<?xml version="1.0" encoding="iso-8859-1" ?><rss version="0.91">
<channel>
<title></title>
<link>http://www.searchforvideo.com</link>
<description>SearchForVideo.com  videos</description>
<language>en-us</language>
<copyright>Copyright 2005 SearchForVideo.com</copyright>
<managingEditor>info@searchforvideo.com</managingEditor>
<webMaster>info@searchforvideo.com</webMaster>

<item>    
<title><![CDATA[ 23533 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF ]]></title>
<link><![CDATA[ http://www.searchforvideo.com//watchclip.php?title=23533+FDA+APPROVES+HERCEPTIN+FOR+THE+ADJUVANT+TREATMENT+OF&link=http%3A%2F%2Fapi.searchvideo.com%2Frd%3Fi%3D534690007%26a%3D274eb77a8bbe365bee32b5722c1be346%26p%3D3%26q%3Ddoxorubicin%26vl%3D501002244%25203173939946%2520536272274%25204141138485%2520175165204%2520708940416%25202128566045%25201755199433%2520359015856%2520525477224%2520&description=FDA+APPROVES+HERCEPTIN+FOR+THE+ADJUVANT+TREATMENT+OF+HER2+POSITIVE+NODE+POSITIVE+BREAST+CANCERGenentech%2C+Inc.+announced+today+that+the+U.S.+Food+and+Drug+Administration++FDA++approved+Herceptin++Trastuzumab++for+the+adjuvant+treatment+of+HER2+positive+node+positive+breast+cancer%2C+as+part+of+a+treatment+regimen+containing+doxorubicin%2C+cyclophosphamide%2C+and+paclitaxel.+The+FDA+approval+was+based+on+data+from+an+interim+joint+analysis+of+more+than+3%2C500+patients+enrolled+in+...&source=AOL+Video&image=http%3A%2F%2Fthumbnails.truveo.com%2F0002%2F47%2F49%2F47496B2051C6A67267B5EE.jpg&category=search ]]></link>
<description><![CDATA[ Source: AOL Video FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE NODE POSITIVE BREAST CANCERGenentech, Inc. announced today that the U.S. Food and Drug Administration  FDA  approved Herceptin  Trastuzumab  for the adjuvant treatment of HER2 positive node positive breast cancer, as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel. The FDA approval was based on data from an interim joint analysis of more than 3,500 patients enrolled in ... ]]> </description>    
</item>
<item>    
<title><![CDATA[ FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2 POSI ]]></title>
<link><![CDATA[ http://www.searchforvideo.com//watchclip.php?title=FDA+APPROVES+HERCEPTIN+FOR+THE+ADJUVANT+TREATMENT+OF+HER2+POSI&link=http%3A%2F%2Fapi.searchvideo.com%2Frd%3Fi%3D502253676%26a%3D274eb77a8bbe365bee32b5722c1be346%26p%3D7%26q%3Dherceptin%26vl%3D1853717663%2520405742896%25203774567898%25201429311564%25202894612026%25201919403634%2520501002244%25202504745025%2520978473184%2520606958591%2520&description=HERCEPTIN+REDUCED+THE+RISK+OF+BREAST+CANCER+RECURRENCE+BY+52+PERCENT+IN+PIVOTAL+STUDIES+++++++ONLY+TARGETED+BIOLOGIC+THERAPY+APPROVED+FOR+USE+IN+ADJUVANT+AND+METASTATIC+HER2+POSITIVE+BREAST+CANCER++++Genentech%2C+Inc.+announced+today+that+the+U.S.+Food+and+Drug+Administration++FDA++approved+Herceptin++Trastuzumab++for+the+adjuvant+treatment+of+HER2+positive+node+positive+breast+cancer%2C+as+part+of+a+treatment+regimen+containing+doxorubicin%2C+cyclophosphamide%2C+and+paclitaxel.+The+FDA+approval+w&source=AOL+Video&image=http%3A%2F%2Fthumbnail.search.aolcdn.com%2Ftruveo%2Fimages%2Fthumbnails%2F7D%2F5B%2F7D5B8EBBD72570.jpg&category=search ]]></link>
<description><![CDATA[ Source: AOL Video HERCEPTIN REDUCED THE RISK OF BREAST CANCER RECURRENCE BY 52 PERCENT IN PIVOTAL STUDIES       ONLY TARGETED BIOLOGIC THERAPY APPROVED FOR USE IN ADJUVANT AND METASTATIC HER2 POSITIVE BREAST CANCER    Genentech, Inc. announced today that the U.S. Food and Drug Administration  FDA  approved Herceptin  Trastuzumab  for the adjuvant treatment of HER2 positive node positive breast cancer, as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel. The FDA approval w ]]> </description>    
</item>
<item>    
<title><![CDATA[ FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF ]]></title>
<link><![CDATA[ http://www.searchforvideo.com//watchclip.php?title=FDA+APPROVES+HERCEPTIN+FOR+THE+ADJUVANT+TREATMENT+OF&link=http%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DC43tB0HXrpA&description=FDA+APPROVES+HERCEPTIN+FOR+THE+ADJUVANT+TREATMENT+OF+HER2+POSITIVE+NODE+POSITIVE+BREAST+CANCERGenentech%2C+Inc.+announced+today+that+the+U.S.+Food+and+Drug+Administration++FDA++approved+Herceptin++Trastuzumab++for+the+adjuvant+treatment+of+HER2+positive+node+positive+breast+cancer%2C+as+part+of+a+treatment+regimen+containing+doxorubicin%2C+cyclophosphamide%2C+and+paclitaxel.+The+FDA+approval+was+based+on+data+from+an+interim+joint+analysis+of+more+than+3%2C500+patients+enrolled+in+...&source=YouTube.com&image=http%3A%2F%2Fi4.ytimg.com%2Fvi%2FC43tB0HXrpA%2Fdefault.jpg&category=search ]]></link>
<description><![CDATA[ Source: YouTube.com FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE NODE POSITIVE BREAST CANCERGenentech, Inc. announced today that the U.S. Food and Drug Administration  FDA  approved Herceptin  Trastuzumab  for the adjuvant treatment of HER2 positive node positive breast cancer, as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel. The FDA approval was based on data from an interim joint analysis of more than 3,500 patients enrolled in ... ]]> </description>    
</item>
</channel>
</rss>
